NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) Director Michael Aaron Kelly acquired 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The shares were purchased at an average cost of $7.60 per share, for a total transaction of $38,000.00. Following the completion of the acquisition, the director now owns 5,000 shares in the company, valued at $38,000. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
NeoGenomics Trading Down 0.4%
Shares of NeoGenomics stock traded down $0.03 during midday trading on Friday, reaching $7.34. 1,266,044 shares of the company's stock traded hands, compared to its average volume of 1,158,151. The stock has a 50 day moving average of $8.54 and a 200-day moving average of $12.39. NeoGenomics, Inc. has a 12 month low of $6.08 and a 12 month high of $19.12. The company has a market cap of $944.62 million, a PE ratio of -11.84 and a beta of 1.60. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The company had revenue of $168.04 million during the quarter, compared to the consensus estimate of $171.38 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm's revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.02) earnings per share. As a group, equities analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have weighed in on NEO shares. Needham & Company LLC lowered their price target on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Bank of America lowered their target price on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Guggenheim initiated coverage on NeoGenomics in a research report on Thursday, May 15th. They set a "neutral" rating on the stock. Wall Street Zen raised NeoGenomics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Piper Sandler set a $12.00 price objective on NeoGenomics and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $13.83.
Check Out Our Latest Research Report on NEO
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in shares of NeoGenomics in the 4th quarter valued at approximately $26,000. Brooklyn Investment Group bought a new position in NeoGenomics in the first quarter worth $35,000. CWM LLC lifted its position in NeoGenomics by 42.6% during the first quarter. CWM LLC now owns 6,299 shares of the medical research company's stock valued at $60,000 after buying an additional 1,883 shares during the period. AlphaQuest LLC bought a new stake in shares of NeoGenomics during the 1st quarter valued at $60,000. Finally, Sterling Capital Management LLC boosted its holdings in shares of NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after buying an additional 3,289 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Articles
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
